loader2
Partner With Us NRI

Aurobindo Pharma Ltd share Price Today

Company details

1,367.30
1,388.05
730.45
1,388.05
6M Return 22.09%
1Y Return 86.41%
Mkt Cap.(Cr) 80,335.17
Volume 1,174,233
Div Yield 0.11%
OI
-
OI Chg %
-
Volume 1,174,233

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Aurobindo Pharma announced Q4FY24 results:

  • Revenue from Operations increased by 17.1% YoY to Rs 7,580 crore with growth across the businesses
  • US formulations (excluding Puerto Rico) revenue increased by 21.6% YoY to Rs 3,588 crore (USD 432 million)
  • Europe formulation revenue increased by 10.4% YoY to Rs 1,832 crore (EUR 203 million)
  • Growth Markets revenue increased by 49.5% YoY to Rs 852 crore (USD 103 million)
  • ARV revenue increased by 31.5% YoY to Rs 238 crore (USD 29 million)
  • API revenue remained flat YoY at Rs 1,019 crore (USD 123 million)
  • EBITDA before Forex and Other income stood at Rs 1,687 crore; EBITDA margin of 22.3%
  • Research & Development (R&D) spend stood at Rs 392 crore, 5.2% of revenues (vs. Q3 FY24: 5.4%)
  • Received final approval for 17 ANDAs including 4 specialty & injectable products from the USFDA
  • Net Profit after Share of Profit/Loss of JV and minority interest at Rs 909 crore, vs. Rs 506 crore in Q4FY23
  • Basic & Diluted EPS grew by 79.5% YoY to Rs 15.51 per share

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “We are extremely delighted to report a strong performance for the quarter and the year, supported by the expansion into the new markets, product launches and stable pricing. Our improved capacity utilization has led to higher operating efficiencies. We are confident of continuing our growth in the upcoming year, while stabilizing the operations of the recently commercialized facilities.”

Result PDF

View Other Company Results

Aurobindo Pharma Ltd shares SWOT Analysis

Strengths (9)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • Strong Annual EPS Growth

Weakness (2)

  • Promoters increased pledged shares QoQ
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (2)

  • Promoter decreasing their shareholding
  • Red Flags: Firms linked to ongoing regulatory investigations/legal cases

Resistance and support

R1 1,383.6
R2 1,396.2
R3 1,404.4
Pivot

1,375.47

S1 1,362.9
S2 1,354.7
S3 1,342.1
EMA SMA
1,287.1
1,234.2
1,174.7
1,075.7
1,266.2
1,230.1
1,153.6
1,079.3
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-01-25 1160.1 1484323 BSE
MARSHALL WACE INVESTMENT STRATEGIES - EUREKA FUND Block Purchase 2024-01-25 1160.1 106480 BSE
MARSHALL WACE INVESTMENT STRATEGIES EUREKA FUND Block Purchase 2024-01-25 1160.1 53641 NSE
Name Category Shares
K NITYANANDA REDDY PROMOTER 4.33%
KIRTHI REDDY KAMBAM PROMOTER 3.46%
M SIVAKUMARAN PROMOTER 2.47%
KAMBAM SPOORTHI PROMOTER 1.19%
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING) PROMOTER 33.51%
AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING) PROMOTER 2.85%
VENKATA RAMPRASAD REDDY PENAKA PROMOTER 3.07%

OUR RESEARCH VIEW

Investment recommendation
Upbeat numbers; future looks more stable…
Call Date
28 May 2024
Entry Price 1,216.00
Target Price 1,475.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Aurobindo Pharma Ltd Stocks COMPARISON

Financials( in Cr) Aurobindo Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 1,371.05 1,579.30 1,510.40 4,570.80 1,184.80
% Change 2.54 -1.20 -0.19 -1.43 0.39
Mcap Cr 80,335.17 378,926.98 121,944.71 121,340.57 119,218.60
Revenue TTM Cr 24,855.38 48,496.85 15,790.60 7,665.00 19,547.40
Net Profit TTM Cr 1,927.65 9,648.44 2,513.47 1,576.00 3,854.40
PE TTM 24.45 37.93 28.66 75.74 30.89
1 Year Return 86.41 51.13 48.56 25.57 103.71
ROCE 9.18 17.20 14.76 16.27 23.94
ROE 7.50 16.13 10.66 12.04 20.64
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 26,839.85 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,424.68 50,451.86
LAST 3M 101,404.97 51,097.20
LAST 6M 186,293.66 40,305.54
LAST 12M 309,547.75 87,515.42
NSE Board Meetings Forthcomming

Jul 18, 2024 l NSE Board Meetings Forthcomming

Aurobindo Pharma announces board meeting date

Jul 15, 2024 l BSE Announcement

Aurobindo Pharma Limited - Board Meeting

Jul 15, 2024 l NSE Announcement

Date Action Type Ratio
Feb 20, 2024 Dividend 150
Nov 20, 2023 Dividend 300
Feb 17, 2023 Dividend 300

Aurobindo Pharma Ltd Information

Stock PE (TTM)
24.45
Promoter Holding
51.8%
Book Value
509.3162
ROCE
9.18%
ROE
7.5%
Description
  • Aurobindo Pharma is a distinguished name in the pharmaceutical industry. It was incorporated in 1986, and its headquarters is located in Hyderabad. As of 31 December 2021, it reported a net income of Rs 604.73 crore. The prominent faces in Aurobindo Pharma management are—Mr K Raghunathan, Mr K Nityananda Reddy, Dr M. Sivakumaran, Mr P. V Ram Prasad Reddy, and a few more. Aurobindo Pharma’s valuation on the stock exchange is Rs 30,636 crore. 

    The company is listed on both the stock exchanges of India, that is NSE and BSE. It is traded under the symbol AURO PHARMA. 

    The company is primarily into the development, manufacturing, and supply of active pharmaceutical ingredients, generic pharmaceuticals, and branded speciality pharmaceuticals. Some key offerings in its product portfolio cater to/include antibiotics, central nervous system, anti-diabetics, gastroenterological, anti-retroviral, and cardiovascular. The company currently supplies its products to more than 150 countries. Its subsidiary company list includes Aurolife Pharma LLC, APL Healthcare, Auro Peptides Ltd, Auronext Pharma Pvt. Ltd. and a few more. 

    Now, if you dive into the company’s financials, you will find the following.

    Aurobindo Pharma’s price-to-equity ratio or PE ratio (6.13) and price-to-book ratio or PB ratio (1.49) are better than the industry’s average. The same is the case with revenue and net income. Over the past five years, Aurobindo Pharma’s revenue and income have grown at an annual rate of 15.2% and 21.38%, respectively. For the same period, the industry’s average income and revenue growth rates were 6.94% and 8.25%, respectively. Aurobindo Pharma’s total liabilities declined by Rs 467.41 crore compared to the financial year 2020. Even after reducing the liabilities, the company cash flow statement shows a free cash flow of Rs 1455.11 crore in FY20-21. 

    On 20 May 2022, the Aurobindo Pharma share price on NSE closed at Rs 557.95. It was 6.71% higher than the previous day’s closing price. The last 52 weeks’ movement of Aurobindo Pharma Ltd.’s share price on the stock market saw a high of Rs 1,043.10 and a low of Rs 520.85. Investing in Aurobindo Pharma shares carries a low amount of risk since its price volatility is 1.95x that of the Nifty.  The key names in its peers’ list are Cipla Ltd., Torrent Pharmaceuticals Ltd., Sun Pharmaceuticals Industries Ltd., and Dr Reddy’s Laboratories Ltd.

    Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.

Registered Address

Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet, Hyderabad, Telangana, 500038

Tel : 91-40-23736370
Email : cs:aurobindo.com; investorgrievances:aurobindo.com
Website : http://www.aurobindo.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524804
NSE Code : AUROPHARMA
Book Closure Date (Month) : Aug
BSE Group : A
ISIN : INE406A01037

FAQ’s on Aurobindo Pharma Ltd Shares

You can buy Aurobindo Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Aurobindo Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jul 16, 2024 03:59 PM the closing price of Aurobindo Pharma Ltd was Rs.1,371.05.

The latest PE ratio of Aurobindo Pharma Ltd as of Jul 16, 2024 03:59 PM is 24.45

The latest PB ratio of Aurobindo Pharma Ltd as of Jul 16, 2024 03:59 PM is 0.37

The 52-week high of Aurobindo Pharma Ltd share price is Rs. 1,388.05 while the 52-week low is Rs. 730.45

According to analyst recommendations, Aurobindo Pharma Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jul 16, 2024 03:59 PM, the market cap of Aurobindo Pharma Ltd stood at Rs. 80,335.17 Cr.

Download App

Download Our App

Play Store App Store
market app